Liquidia Technologies (LQDA)
NASDAQ:LQDA
Want to see LQDA full AI Analyst Report?
LQDA Stock Chart & Stats
$39.47
<$0.01(<0.01%)
At close: 4:00 PM EST
$39.47
<$0.01(<0.01%)
Day’s Range― - ―
52-Week Range$11.85 - $73.22
Previous CloseN/A
Volume97.81K
Average Volume (3M)2.44M
Market Cap
$6.32B
Enterprise Value$6.07B
Total Cash (Recent Filing)$222.79M
Total Debt (Recent Filing)$184.82M
Price to Earnings (P/E)280.4
Beta1.69
Next Earnings
Aug 06, 2026EPS Estimate
0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.24
Shares Outstanding88,928,100
10 Day Avg. Volume3,240,524
30 Day Avg. Volume2,435,842
Financial Highlights & Ratios
PEG Ratio0.83
Price to Book (P/B)66.33
Price to Sales (P/S)18.75
P/FCF Ratio-74.16
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue21.06
Enterprise Value/Gross Profit22.95
Enterprise Value/Ebitda112.78
Forecast
1Y Price Target
$74.50Price Target Upside88.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)3.35
Revenue Forecast (FY)$724.86M
Bulls Say, Bears Say
Bulls Say
Profitability InflectionLiquidia's shift to sustained product-driven profitability marks a structural change: recurring YUTREPIA sales produced positive operating profit and net income, turning multi-year losses into a profitable model. Durable product revenue reduces refinancing risk and supports reinvestment in commercialization and trials over the next 2-6 months.
Cash Generation And Self-FundingRobust cash balances and positive free cash flow provide lasting financial flexibility: operating cash coverage funds manufacturing expansion and clinical programs without near-term reliance on external capital. This materially lowers dilution risk and enables execution of strategic investments over the medium term if sales momentum persists.
Rapid Commercial AdoptionStrong market share gains and prescriber depth indicate durable competitive positioning: high conversion rates and rising number of physicians treating multiple patients suggest stickier demand and successful clinical adoption. This establishes scale advantages, supports gross margins, and makes continued share gains more achievable over coming quarters.
Bears Say
Patent Litigation RiskOngoing patent litigation introduces material structural uncertainty: adverse rulings or delays could enable generic entry, injunctions, or costly settlements that materially reduce YUTREPIA revenue and impair long-term cash generation. Legal outcomes are binary and timing-uncertain, posing sustained downside risk to the commercial franchise.
Balance Sheet LeverageAlthough leverage has improved, absolute debt remains sizable relative to equity, which constrains strategic optionality. Meaningful debt increases interest obligations and can limit ability to pursue large investments or acquisitions; in a downturn, leverage can force tougher financing decisions or slow program timelines.
Commercial Execution RiskThe company's growth roadmap relies on continued prescriber uptake, successful transitions from competitors, and expansion into underdiagnosed PH-ILD markets. Market education needs and patient convenience (dosing frequency) are structural adoption headwinds; failure to sustain momentum would slow revenue scaling and pressure margins and cash generation.
Liquidia Technologies News
LQDA FAQ
What was Liquidia Technologies’s price range in the past 12 months?
Liquidia Technologies lowest stock price was $11.85 and its highest was $73.22 in the past 12 months.
What is Liquidia Technologies’s market cap?
Liquidia Technologies’s market cap is $6.32B.
When is Liquidia Technologies’s upcoming earnings report date?
Liquidia Technologies’s upcoming earnings report date is Aug 06, 2026 which is in 42 days.
How were Liquidia Technologies’s earnings last quarter?
Liquidia Technologies released its earnings results on May 11, 2026. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.11.
Is Liquidia Technologies overvalued?
According to Wall Street analysts Liquidia Technologies’s price is currently Undervalued.
Does Liquidia Technologies pay dividends?
Liquidia Technologies does not currently pay dividends.
What is Liquidia Technologies’s EPS estimate?
Liquidia Technologies’s EPS estimate is 0.76.
How many shares outstanding does Liquidia Technologies have?
Liquidia Technologies has 88,928,100 shares outstanding.
What happened to Liquidia Technologies’s price movement after its last earnings report?
Liquidia Technologies reported an EPS of $0.52 in its last earnings report, beating expectations of $0.41. Following the earnings report the stock price went up 25.603%.
Which hedge fund is a major shareholder of Liquidia Technologies?
Currently, no hedge funds are holding shares in LQDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Liquidia Technologies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$74.50 (88.75% Upside)
$74.50 (88.75% Upside)
Blogger Sentiment
Bullish
LQDA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 25.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $102.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.6%
Last 30 Days ▲ 13.4%
Last 30 Days ▲ 13.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
448.18%
12-Months-Change
Fundamentals
Return on Equity
46.82%
Trailing 12-Months
Asset Growth
76.55%
Trailing 12-Months
Company Description
Liquidia Technologies
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
LQDA Company Deck
LQDA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum: rapid revenue and profitability growth, expanding market share, growing prescription breadth and depth, and a well-funded clinical pipeline. Primary risks cited were legal uncertainty, the need for continued market education (especially in PH-ILD and community settings), dosing convenience considerations (addressable by L606), and timing of broader indication studies. Overall, positives substantially outweigh the challenges described.View all LQDA earnings summariesLQDA Stock 12 Month Forecast
Average Price Target
$74.50
▲(88.75% Upside)
Technical Analysis
Ocular Therapeutix
―
Adaptive Biotechnologies
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Recursion Pharmaceuticals
―
Ownership Overview
30.85% Insiders
8.31% Mutual Funds
39.17% Other Institutional Investors
5.00% Public Companies and Individual Investors